S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
T   38.00 (-4.11%)
PRI   131.64 (+0.41%)
BAC   32.94 (-0.06%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
T   38.00 (-4.11%)
PRI   131.64 (+0.41%)
BAC   32.94 (-0.06%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
T   38.00 (-4.11%)
PRI   131.64 (+0.41%)
BAC   32.94 (-0.06%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
CGC   15.32 (+7.74%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
T   38.00 (-4.11%)
PRI   131.64 (+0.41%)
BAC   32.94 (-0.06%)
DIS   148.38 (+0.49%)
Log in

Aridis Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ARDS)

$5.14
+0.32 (+6.64 %)
(As of 11/19/2019 04:00 PM ET)
Today's Range
$4.98
Now: $5.14
$5.14
50-Day Range
$4.55
MA: $5.78
$7.09
52-Week Range
$4.39
Now: $5.14
$12.45
Volume80 shs
Average Volume4,421 shs
Market Capitalization$45.80 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.9
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDS
CUSIPN/A
CIKN/A
Phone408-385-1742

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value$3.25 per share

Profitability

Net Income$-22,100,000.00
Net Margins-660.52%

Miscellaneous

Employees23
Market Cap$45.80 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.


Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 13th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.54. Aridis Pharmaceuticals had a negative return on equity of 182.31% and a negative net margin of 660.52%. View Aridis Pharmaceuticals' Earnings History.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

What price target have analysts set for ARDS?

4 brokers have issued twelve-month target prices for Aridis Pharmaceuticals' shares. Their forecasts range from $15.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' stock price to reach $21.75 in the next twelve months. This suggests a possible upside of 323.2% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

What is the consensus analysts' recommendation for Aridis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

Has Aridis Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARDS stock have been trending very negative on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Aridis Pharmaceuticals.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 14,600 shares, an increase of 71.8% from the September 30th total of 8,500 shares. Based on an average daily trading volume, of 10,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.3% of the company's shares are sold short. View Aridis Pharmaceuticals' Current Options Chain.

Who are some of Aridis Pharmaceuticals' key competitors?

What other stocks do shareholders of Aridis Pharmaceuticals own?

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the folowing people:
  • Dr. Eric J. Patzer, Exec. Chairman (Age 70)
  • Dr. Vu L. Truong, Founder, CEO, Chief Scientific Officer & Director (Age 55)
  • Dr. Alan H. Cohen, Sr. VP of Clinical & Medical Affairs (Age 58)
  • Mr. Fred Kurland, Chief Financial Officer (Age 68)
  • Mr. Jeffrey J. Fessler J.D., Acting Gen. Counsel (Age 56)

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $5.14.

How big of a company is Aridis Pharmaceuticals?

Aridis Pharmaceuticals has a market capitalization of $45.80 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]


MarketBeat Community Rating for Aridis Pharmaceuticals (NASDAQ ARDS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel